Abstract
A refractory duodenal ulcer was arbitrarily defined as one that had failed to heal completely after treatment with cimetidine 1 g daily for three months. Of 66 patients with refractory duodenal ulcer, healing eventually occurred in 37 patients, after treatment for an average of 7.4 months. But 28 patients did not heal despite treatment for an average of 9.4 months; and one patient defaulted. In 41 patients the daily dose of cimetidine was increased to 2 g: the ulcers in 31 patients healed. In eight patients the daily dose was increased to 3 g and healing occurred in four patients. Eighteen patients required admission on 22 occasions because of severe symptoms despite treatment. Nine patients underwent surgery but in five the results were poor. Differences in clinical and endoscopic features between refractory and non-refractory ulcer patients were small. Acid and pepsin secretion were similar and gastrin concentrations normal. Blood levels of the drug and suppression of acid secretion were both satisfactory. Identification of refractory ulcer patients at the start of treatment was therefore not possible. Refractoriness could occur at any time during the course of the disease, previous treatment with cimetidine often having resulted in rapid healing, but subsequent relapses were also usually refractory. The cause of refractoriness remains unknown and the rather poor results of surgery in this series suggests that optimal management of these patients remains to be determined. Refractoriness probably indicates a changed natural history of the disease and in some patients a more poor prognosis.
Full text
PDF






Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bianchi Porro G., Prada A., Petrillo M., Lazzaroni M. Women and duodenal ulcer. Br Med J (Clin Res Ed) 1981 Jul 18;283(6285):235–235. doi: 10.1136/bmj.283.6285.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bodemar G., Norlander B., Walan A., Larsson R. Short- and long-term treatment with cimetidine in peptic ulcer disease and the pharmacokinetics of cimetidine. Scand J Gastroenterol Suppl. 1979;55:96–106. [PubMed] [Google Scholar]
- Brater D. C., Peters M. N., Eshelman F. N., Richardson C. T. Clinical comparison of cimetidine and ranitidine. Clin Pharmacol Ther. 1982 Oct;32(4):484–489. doi: 10.1038/clpt.1982.192. [DOI] [PubMed] [Google Scholar]
- Festen H. P., Diemel J., Lamers C. B., van Schaik A., Tangerman A., van Tongeren J. H. Is the measurement of blood cimetidine levels useful? Br J Clin Pharmacol. 1981 Sep;12(3):417–421. doi: 10.1111/j.1365-2125.1981.tb01237.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gray G. R., McWhinnie D., Smith I. S., Gillespie G. Five-year study of cimetidine or surgery for severe duodenal ulcer dyspepsia. Lancet. 1982 Apr 3;1(8275):787–788. doi: 10.1016/s0140-6736(82)91823-2. [DOI] [PubMed] [Google Scholar]
- Gugler R., Fuchs G., Dieckmann M., Somogyi A. A. Cimetidine plasma concentration-response relationships. Clin Pharmacol Ther. 1981 Jun;29(6):744–748. doi: 10.1038/clpt.1981.105. [DOI] [PubMed] [Google Scholar]
- Hannigan B. G. Duodenal ulcer in servicemen. J R Army Med Corps. 1980 Oct;126(3):133–134. doi: 10.1136/jramc-126-03-05. [DOI] [PubMed] [Google Scholar]
- Hasan M., Sircus W. The factors determining success or failure of cimetidine treatment of peptic ulcer. J Clin Gastroenterol. 1981 Sep;3(3):225–229. doi: 10.1097/00004836-198109000-00005. [DOI] [PubMed] [Google Scholar]
- Ishague M., Bardhan K. D. An assessment of the radial diffusion method for the measurement of pepsin in gastric secretion and its comparison with the haemoglobin substrate colorimetric method. Clin Chim Acta. 1978 Jul 15;87(2):259–263. doi: 10.1016/0009-8981(78)90346-7. [DOI] [PubMed] [Google Scholar]
- Massarrat S., Eisenmann A. Factors affecting the healing rate of duodenal and pyloric ulcers with low-dose antacid treatment. Gut. 1981 Feb;22(2):97–102. doi: 10.1136/gut.22.2.97. [DOI] [PMC free article] [PubMed] [Google Scholar]
- McCarthy D. M. Report on the United States experience with cimetidine in Zollinger-Ellision syndrome and other hypersecretory states. Gastroenterology. 1978 Feb;74(2 Pt 2):453–458. [PubMed] [Google Scholar]
- Mohammed R., Mitchell K. G., Mackay C. The treatment of "cimetidine resistant" peptic ulcers by ranitidine hydrochloride: a new histamine H2-receptor antagonist. Curr Med Res Opin. 1981;7(8):523–525. doi: 10.1185/03007998109112368. [DOI] [PubMed] [Google Scholar]
- Peden N. R., Boyd E. J., Wormsley K. G. Women and duodenal ulcer. Br Med J (Clin Res Ed) 1981 Mar 14;282(6267):866–866. doi: 10.1136/bmj.282.6267.866. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Roberts D. M., Wilson J. A., Ratcliffe G. E., Waring A. J., Reilly M. J., Lloyd J. S. Clinical trial of ranitidine in the treatment of peptic ulcer. Br J Clin Pract. 1982 Jan;36(1):9–12. [PubMed] [Google Scholar]
- Ruen S. J., Hesselfeldt P., Larsen N. E. Clinical and pharmacological effectiveness of cimetidine in duodenal ulcer patients. Scand J Gastroenterol. 1979;14(4):489–492. [PubMed] [Google Scholar]
- Sonnenberg A., Müller-Lissner S. A., Vogel E., Schmid P., Gonvers J. J., Peter P., Strohmeyer G., Blum A. L. Predictors of duodenal ulcer healing and relapse. Gastroenterology. 1981 Dec;81(6):1061–1067. [PubMed] [Google Scholar]
- Webster J., Barber H. E., Hawksworth G. M., Jeffers T. A., Petersen J., Petrie J. C., Brunt P. W., Mowat N. A., Griffiths R. Cimetidine-a clinical and pharmacokinetic study. Br J Clin Pharmacol. 1981 Apr;11(4):333–338. doi: 10.1111/j.1365-2125.1981.tb01129.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Witzel L., Wolbergs E. Peptic ulcer healing with ranitidine in cimetidine resistance. Lancet. 1982 Nov 27;2(8309):1224–1224. doi: 10.1016/s0140-6736(82)91247-8. [DOI] [PubMed] [Google Scholar]
